Skip to main content
. 2019 Jul 5;10:2987. doi: 10.1038/s41467-019-10839-0

Table 1.

Treatment conditions of primary human lung fibroblasts

Compound Final concentration Solvent
GSK621 10 µMa DMSO
Metformin 1 mM, 5 mM,10 mM DMEM
Nintedanib 1 µMa DMSO
Noggin 200 ng/mL Noggin reconstitution buffer
Pirfenidone 0.3 mg/mLa Ethanol
Selumetinib 5 µMa DMSO
rhTGFβ1 2 ng/mL rhTGFβ1 reconstitution buffer
rhBMP2 50 ng/mLa rhBMP2 reconstitution buffer

aDosage was chosen based on a literature search and the dose showing highest efficacy was selected